Skip to main content
CTS $63.47 +1.44%
CTS logo

CTS · Cts Corp

Track CTS — free
$63.47 +0.90 (+1.44%) At close · Aug 14
Market Cap
$1.81B
Shares
28.59M
All earnings calls

Earnings call · FY2025 Q4

Cts Corp Q4 FY2025 Earnings Call

Cts Corp Q4 FY2025 Earnings Call

Concluded Feb 10, 2026 Audio replay
Feb 10, 2026 36:39 43 turns
Period
FY2025 Q4
Runtime
36:39
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

CTS reported Q4 sales of $137 million, up 9% year over year, driven by 16% growth in diversified end markets (now 57% of revenue), with adjusted gross margin expanding 150 bps to 39.1% and adjusted EPS of $0.62. Full-year 2025 sales rose 5% to $541 million, and the company guided 2026 sales to $550–$580 million with adjusted EPS of $2.30–$2.45.

Transportation market outlook 27 Diversification strategy and end-market mix 14 Margin expansion and profitability 13 Industrial market recovery 11 Aerospace and defense 8 Innovation, new products and strategy execution 8

Management tone

Confident

Net tone +62 · low hedging

Grounding quotes
  • “we delivered strong performance with revenue growth of 9% year over year, with our diversified end markets growing 16% versus the prior year period”
  • “Our pipeline remains strong with backlog levels supporting future growth.”
  • “Medical bookings showed robust growth driven by continued strength in therapeutic applications”
  • “We're a little bit conservative. We haven't called it bottom. We'd like to get a quarter of data or two behind us, but you can tell we're definitely trending in that direction.”

Forward guidance

2 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $137.27M +8.5% YoY
Gross margin · derived Q4 39.1% +2.0 pp YoY
Net income · derived Q4 $19.74M +70.7% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Q4 sales grew 9% year over year to $137 million, with diversified end markets up 16%
  • Q4 adjusted gross margin expanded 150 bps to 39.1%; full-year adjusted gross margin also up 150 bps to 38.5%
  • Q4 adjusted diluted EPS of $0.62, up from $0.50 in Q4 2024; full-year adjusted EPS of $2.23, up from $2.12
  • Medical Q4 sales up 41% YoY; full-year medical sales up 21% to $85 million with bookings up 37% in Q4
  • Industrial Q4 sales up 16% YoY; full-year industrial sales up 12% to $140 million with Q4 bookings up 22% and full-year book-to-bill of 1.11
  • Q4 net income reached $20 million (14.4% of sales) vs. $12 million (9.1%) a year ago; full-year operating cash flow up $4 million to $102 million

Risks & pressure points

  • Transportation Q4 sales declined 1% YoY (essentially flat) and full-year transportation sales decreased 7%
  • Aerospace & defense Q4 sales were down 4% YoY due to timing of certain programs, and Q4 defense bookings were down
  • Full-year aerospace & defense bookings growth of 15% partially offset the Q4 weakness, but Q4 SideQuest revenues of $6 million were depressed by government funding cycles
  • M&A pipeline is active but no transactions to report, with management noting valuations are still high
  • China transportation market characterized as having 'reached the new normal' with engagement limited primarily to transplant OEMs and select local Chinese customers
  • Management is not yet calling a bottom in transportation, expecting a lighter first half of 2026 versus the second half

Key moments

Jump directly to management's words in the synchronized transcript.

“Our medical end market delivered strong performance in the fourth quarter, with sales increasing 41% versus the prior year period. Reflecting the strong growth momentum across our medical portfolio, particularly in therapeutic applications, where we're seeing robust demand.” Kieran O'Sullivan, CEO

Forward guidance

From the 8-K filed Feb 10, 2026.

Metric Guided
Full-year 2026 sales
full-year 2026
$550M – $580M
Adjusted diluted EPS
full-year 2026
$2.30 – $2.45

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived
$16.63M
Dividend / share
$0.04
Full-screen source Call document